BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Faces Analyst Downgrade as Obesity Market Expectations Plateau
Eli Lilly Faces Analyst Downgrade as Obesity Market Expectations Plateau
20
3
BTCCSquare news:
Berenberg analyst Kerry Holford downgraded Eli Lilly (LLY) from Buy to Hold, trimming the price target from $970 to $830. The MOVE reflects a belief that the obesity market upgrade cycle has peaked, despite Lilly's continued dominance in diabetes and weight-loss treatments like Zepbound.
Physicians still prefer Lilly's Zepbound over Novo Nordisk's Wegovy, but consensus expectations now fully price in the company's market leadership. The stock's 400% five-year gain far outpaces the sector's 70% average, but recent performance has cooled with a 16% decline over the past year.
By:
